10:33:46 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Sernova Corp
Symbol SVA
Shares Issued 131,477,831
Close 2015-03-04 C$ 0.185
Market Cap C$ 24,323,399
Recent Sedar Documents

Sernova to list Holler et al. for board at April 28 AGM

2015-03-05 06:45 ET - News Release

Mr. Frank Holler reports

SERNOVA ANNOUNCES ANNUAL MEETING AND NOMINEES FOR ITS BOARD OF DIRECTORS

Sernova Corp. will hold its annual general and special meeting of shareholders on April 28, 2015. The record date for shareholders entitled to vote at the AGM is March 20, 2015.

The company also wishes to announce that management's nominees for the board of directors at the upcoming AGM are Frank Holler, Jeffrey Bacha, James Parsons, Bruce Weber and Dr. Philip Toleikis.

After a lengthy and productive tenure as chairman, Dr. George Adams has advised the board that he will be retiring as a director of Sernova at the end of his term and has stepped down as chairman of the board.

Dr. Toleikis, president and chief executive officer of Sernova, said: "On behalf of the board of directors, I would like to extend my sincere appreciation to Dr. Adams for his substantial contributions to Sernova during his eight years of board membership. Under his leadership, George provided a strong foundation upon which Sernova can advance to its next stage of growth. We wish him every success in his future endeavours."

The company is pleased to announce that Mr. Holler has been appointed chairman of the board.

Mr. Holler brings a wide range of experience to his role as Sernova's chairman of the board. An active investor and successful entrepreneur, Mr. Holler is currently the chief executive officer and fund manager for BC Advantage Funds. He previously served as president and chief executive officer of Xenon Pharmaceuticals Inc., a Nasdaq Stock Market-listed genomics-based drug development company, from 1999 to 2003; as president and chief executive officer of ID Biomedical Corp., a Nasdaq-listed vaccine development company sold to GlaxoSmithKline PLC in 2005, from 1991 to 1998; and as a founding director of Angiotech Pharmaceuticals, a Toronto Stock Exchange-/Nasdaq-listed medical device company which developed and partnered one of the world's first drug-eluting stents, from 1992 to 1997.

"We are delighted that Frank has agreed to step in to an active role as Sernova's board chair," added Dr. Toleikis. "Frank's deep experience in the biopharma industry and in technology capital markets will be crucial as Sernova continues to progress its clinical programs and partnership activities towards commercialization."

Prior to working in biotechnology and health care, Mr. Holler was an investment banker with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).

Mr. Holler currently serves on the board of directors of BC Advantage Funds (VCC) Ltd. (chairman), Contech Enterprises Inc., the Prevention of Organ Failure Centre (chairman) at St. Paul's Hospital, Sernova and Xenon Pharmaceuticals. He has previously served on the board of directors of Protox Therapeutics Inc. (Chairman), Allon Therapeutics Inc., Aquinox Pharmaceuticals Inc., Cantest Inc., In Motion Technologies Inc., Genome British Columbia, Providence Health Care and Redlen Technologies Inc. He was also previously a director of the British Columbia Biotechnology Association from 1992 to 1998 and, in 2003, received the B.C. Biotech Award for Vision and Leadership.

Mr. Holler holds a master of business administration and bachelor of arts (economics) from the University of British Columbia.

For purposes of the AGM, in accordance with the terms of the adopted advance notice bylaw, the board has determined that such notice of nominations of persons for election to the board at the AGM must be made by March 18, 2015. Such notice must be in the form, and given in the manner, prescribed by the advance notice bylaw, and the chief executive officer of the company has stipulated his company e-mail address as an e-mail address for receipt of such notice.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.